Straits Times Index
3,280.10 -7.65 (-0.23%) Nikkei
37,934.76 +306.28 (+0.81%) Hang Seng
17,651.15 +366.61 (+2.12%) FTSE 100
8,139.83 +60.97 (+0.75%) Bitcoin USD
63,864.00 +881.16 (+1.40%) CMC Crypto 200
1,345.49 -51.04 (-3.64%)
Carl Zeiss Meditec AG (AFX.DE)
| Previous close | 99.00 |
| Open | 99.65 |
| Bid | 101.00 x 18700 |
| Ask | 101.00 x 15000 |
| Day's range | 99.20 - 101.10 |
| 52-week range | 72.60 - 123.75 |
| Volume | |
| Avg. volume | 132,706 |
| Market cap | 8.971B |
| Beta (5Y monthly) | 0.90 |
| PE ratio (TTM) | 32.35 |
| EPS (TTM) | 3.10 |
| Earnings date | 08 May 2024 |
| Forward dividend & yield | 1.10 (1.10%) |
| Ex-dividend date | 22 Mar 2024 |
| 1y target est | 154.33 |
Simply Wall St.What Does Carl Zeiss Meditec AG's (ETR:AFX) Share Price Indicate?
Carl Zeiss Meditec AG ( ETR:AFX ), might not be a large cap stock, but it received a lot of attention from a...
PR NewswireCarl Zeiss Meditec AG Completes Acquisition of Dutch Ophthalmic Research Center (D.O.R.C.); Companies Unite to Shape Ophthalmology Market
Carl Zeiss Meditec AG announced today that, after securing all required regulatory approvals, it has completed the acquisition of 100% of D.O.R.C. (Dutch Ophthalmic Research Center) from the investment firm Eurazeo SE, Paris, France. The acquisition enhances and complements ZEISS Medical Technology's broad ophthalmic portfolio and range of digitally connected workflow solutions for addressing a wide variety of eye conditions, spanning retina and cornea disorders, cataract, glaucoma, and refracti
CNW GroupZEISS Sets Stage for Future of Ophthalmic Surgery and 3D Visualization at ASCRS 2024
ZEISS Medical Technology will showcase the latest in 3D visualization technology and surgical innovation at the American Society of Cataract and Refractive Surgery (ASCRS) conference from April 5-8, 2024, in Boston, MA. Building on its ZEISS Medical Ecosystem, several of the new innovations enable seamless data integration and management across the cataract and refractive workflows, creating a new standard for efficient, personalized ophthalmic care.
